1 SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report JANUARY 21, 2000 BARR LABORATORIES, INC. (Exact name of registrant as specified in its charter) New York 1-9860 22-1927534 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) Two Quaker Road, P.O. Box 2900, Pomona, New York 10970-0519 (Address of principal executive offices) (Zip code) (914) 362-1100 (Registrant's telephone number, including area code) 2 BARR LABORATORIES, INC. CURRENT REPORT DATED JANUARY 21, 2000 Item 5. Other Events See attached Exhibit 99.1, press release announcing the signing of a letter of intent to establish a strategic relationship with DuPont Pharmaceuticals Company to develop, market and promote five (5) different proprietary products and, upon finalization of the agreements, to terminate all litigation between the two companies. Item 7. Financial Statements and Exhibits (c) Exhibit Number Exhibit -------------- ------- 99.1 Registrant's January 20, 2000 press release announcing the signing of a letter of intent to establish a strategic relationship with DuPont Pharmaceuticals Company to develop, market and promote five (5) different proprietary products and, upon finalization of the agreements, to terminate all litigation between the two companies. 2 3 BARR LABORATORIES, INC. CURRENT REPORT DATED JANUARY 21, 2000 SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BARR LABORATORIES, INC. Date: January 21, 2000 /S/ William T. McKee -------------------- William T. McKee Chief Financial Officer 3